Medical Devices Vascular comparable sales growth measures year-over-year growth in Abbott's Vascular franchise on the company's comparable basis.
Abbott reported 5.1% comparable sales growth in Vascular in the second quarter of 2026.
Vascular grew more slowly than the total device portfolio
Medical Devices comparable growth was 8.4% in the same quarter.
That gap helps investors identify which franchises are contributing above or below the segment growth rate.
Comparable growth removes specified non-operating distortions
The measure is designed to remove specified acquisition, divestiture, and foreign-exchange effects.
Read it with Medical Devices comparable growth and Structural Heart comparable growth.
Primary source: Abbott Q2 2026 earnings release filed with the SEC.
Part of the Medical Device Portfolio Growth
See It in Company Research
These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.
- ABTOpen operating-model research →10 of 10 reviewed concepts in Medical Device Portfolio GrowthCardiovascular franchise mix6 of 6 bridge concepts supportedContinue through this bridge:Electrophysiology GrowthHeart Failure GrowthNeuromodulation GrowthRhythm Management GrowthStructural Heart Growth
Continue Research
Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.
Compare medical device portfolio growth
Compare Vascular franchise growth against faster-growing Medical Devices categories.
Explore more topics in the Financial Research Encyclopedia.